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Hypoxic tumours are a major problem for cancer photodynamic therapy. Here we show that 
photo-redox catalysis can provide an oxygen-independent mechanism of action to combat 
this problem. We have designed a highly oxidative Ir(III) photo-catalyst, [Ir(ttpy)(pq)Cl]PF6 
([1]PF6, ttpy = 4'-(p-tolyl)-2,2':6',2''-terpyridine, pq = 3-phenylisoquinoline), which is photo-
toxic towards both normoxic and hypoxic cancer cells. Complex 1 photo-catalytically 
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oxidizes nicotinamide adenine dinucleotide (NADH), an important coenzyme in living cells, 
generating NAD• radicals with high turnover frequency in biological media. Moreover, 
complex 1 and NADH synergistically photo-reduce cytochrome c under hypoxia. Density 
functional theory calculations reveal p-stacking in adducts of 1 and NADH, facilitating 
photo-induced single electron transfer. In cancer cells, 1 localizes in mitochondria and 
disrupts electron transport via NADH photo-catalysis. Upon light irradiation, 1 induces 
NADH depletion, intracellular redox imbalance, and immunogenic-apoptotic cancer cell 
death. This photo-catalytic redox imbalance strategy offers a new approach for efficient 
cancer phototherapy. 
Platinum compounds are the most widely used anticancer drugs in the clinic1. However, new 
generations of metal-based anticancer agents are urgently needed to combat drug resistance 
and reduce side-effects2,3. Photo-activated metal complexes can provide both temporal and 
spatial control over drug activation and show remarkable potential for cancer treatment4-8. 
Tin, lutetium, palladium and ruthenium based photosensitizers (PSs) are, or were, currently in 
clinical trials for cancer photodynamic therapy (PDT)9,10. The catalytic nature of PDT can 
achieve high therapeutic efficacy at low doses11, and, in general, does not show cross 
resistance to chemotherapy, helpful for overcoming drug resistance12.  However, a few cases 
of clinical resistance to PSs are emerging13-21.The mechanisms of PDT resistance include 
hypoxia13, detoxification by intracellular antioxidants systems,14,15 induction of stress 
response genes,16-20 and drug efflux by P-glycoprotein21. These considerations indicate the 
urgency of developing new generations of PSs and novel mechanisms of action (MOA) for 
cancer phototherapy. The high dependence of the MOA of PDT on oxygen restricts its 
application, since cancer cells grow mostly under hypoxia22. We have therefore investigated 
novel PSs with new MOAs against hypoxic cancer cells. 
Although most tumours adopt a Warburg-type glycolytic metabolism, Reactive Oxygen 
Species (ROS) released from the mitochondrial electron transport chain (ETC) are essential 
for cell proliferation and redox regulatory functions of cancer cells under hypoxia23. The 
electron source in the ETC is 1,4-dihydronicotinamide adenine dinucleotide (NADH, Fig. 
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1a), which participates in the maintenance of the intracellular redox balance and as a 
coenzyme in >400 oxidoreductases24. We hypothesise that selective induction of NADH 
depletion and of ETC disruption in cancer cells may destroy the intracellular redox balance 
and kill cancer cells under hypoxia. 
Photo-catalysts which induce single electron transfer (SET) between substrates have 
achieved great success in organic synthesis25. It is notable that most reported photoredox 
catalysis has been carried out in degassed organic solvents26. An oxygen-independent MOA 
is appealing for NADH photo-catalysis in hypoxic cancer cells. However, strong triplet 
excited-state quenching by water and oxygen severely limits the application of traditional 
photo-catalysts in biological systems27.  
Here we have synthesised and characterised a novel stable iridium photo-catalyst (1, Fig. 
1b) with an unusually high excited state redox potential compared to common PSs25. 
Strikingly, upon light irradiation in biological media, complex 1 shows more than two orders 
of magnitude higher NADH turnover frequency (TOF) than organometallic half-sandwich 
catalysts28. Moreover, 1 can photo-catalyse cytochrome c (cyt c) reduction in the presence of 
NADH under hypoxia. We have carried out detailed experimental and computational studies 
on photo-catalytic NADH oxidation in aqueous media, involving the trapping of NAD• 
radicals and their characterisation. In addition, complex 1 targets mitochondria in cancer 
cells, and, importantly, shows almost equivalent photo-cytotoxicity under normoxia and 
hypoxia, as well as low toxicity to unirradiated normal cells. 
 
Results  
Photosensitizer design and characterisation 
Complex 1 was characterised by analytical and spectroscopic data, and x-ray crystallography 
(Fig. 1c, Supplementary Tables 1, 2). Ir(III) photoredox catalysts with bidentate ligands often 
exist as a mixture of enantiomers29. The incorporation of tridentate ligands can avoid 
chirality30, as in the present case (Fig. 1c). Density functional theory (DFT）calculations 
confirmed that the  
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trans C-Cl isomer found in the crystal structure is 33.5 kJ mol-1 more stable than the cis C-Cl 
isomer. Complex 1 showed absorption between 350-480 nm (Supplementary Fig. 1), which 
matched well with spectra calculated by time-dependent DFT (TD-DFT; Supplementary Fig. 
2), with low-lying metal-to-ligand charge-transfer states (MLCT, Supplementary Table 3).  
The phosphorescence of complex 1 was sensitive to solvent polarity (Supplementary Fig.3, 
Supplementary Table 4) with emission at ca. 562 nm similar to the calculated data (567 nm, 
Supplementary Table 3) at 293 K. Moreover, oxygen strongly influenced the 
phosphorescence intensity and lifetime of 1 (Supplementary Figs. 4,5, Supplementary Table 
4), being longer in acetonitrile (743.7/1390.3 ns, air/N2) than in phosphate buffered saline 
(PBS, 330.8/382.3 ns, air/N2). The lowest energy singlet excited state S1 arises from LUMO 
ß HOMO excitation and showed both ligand-to-ligand charge-transfer 1LL(C^N®ttpy)CT and 
MLCT character (Supplementary Table 3, Supplementary Fig. 6). Upon light excitation, the 
excited triplet transition “hole” (Fig. 2a) is localised on the  p-system of the C^N ligand, 
while the “particle” is localised on the N^N^N ligand. In addition, complex 1 exhibited 
strong two-photon absorption (TPA) (Fig. 2b), observed with a maximum at ca. 760 nm 
(Supplementary Fig. 7) and a two-photon absorption cross section of 160 Goeppert-Mayer 
(GM).  
 
 
Ideally, efficient photo-catalytic drugs should exhibit high dark- and photo-stability. 
Complex 1 showed excellent stability in both organic solvents, e.g. DMSO (Supplementary 
Fig. 8), RPMI-1640 cell culture medium (Fig. 2c), and human serum (Supplementary Fig. 9) 
on prolonged incubation. Additionally, 1 also exhibited no photo-degradation under 463 nm 
blue-light irradiation in PBS (Fig. 2d).  
Cyclic voltammetry revealed a significantly different redox behavior in the ground and 
excited states of 1 (Supplementary Table 5). The excited-state redox potential of 1 (E1/2*III/II = 
+1.22 V vs SCE, E1/2IV/*III = -0.48 V vs SCE) is higher than for reported Ru(II) or Ir(III) 
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photocatalysts (Supplementary Fig. 10, Supplementary Table 5)24. DFT calculations also 
confirmed that the triplet excited state of 1 switched character with the ground state 
(Supplementary Fig. 11) in terms of reductant-to-oxidant behavior (Supplementary Table 6), 
and thus is a strong excited-state oxidant (Supplementary Table 7). 
 
Photo-catalytic oxidation of NADH under normoxia 
The catalytic photo-oxidation of NADH (3 mM) by 1 (0.25 mM) in H2O/D2O/CD3OD 
(0.5/49.5/50, v/v, 4 mM NaCl) was monitored by 1H NMR spectroscopy at 298 K. In the dark, 
the sample remained unchanged for 24 h. In contrast, ca. 95% of the NADH was oxidised to 
NAD+ after irradiation (463 nm, 30 min), while 1 remained intact (Supplementary Fig. 12). 
The photo-catalytic efficiency of 1 (6 µM) towards NADH (240 µM) in PBS was 
quantified by UV-vis spectroscopy (Supplementary Fig. 13). Upon photoirradiation (463 nm) 
in air, the absorbance of NADH at 339 nm decreased gradually (Fig. 3a), and the conversion 
of NADH to NAD+ was confirmed by mass spectrometry (Supplementary Fig. 14). A plot of 
lnA339 versus time revealed first-order kinetics with a rate constant k of 1.77 ´ 10-2 min-1 
(Supplementary Fig. 15). The highest observed NADH oxidation turnover number (TON) 
was 50.2 with a turnover frequency (TOF) of 100.4 h-1 (Supplementary Table 8), much higher 
than the reported (non-photoactivated) Ir(III) half-sandwich catalyst [(h5-
Cpxbiph)Ir(phpy)py]PF6 (TOF = 0.83 h-1)27. Moreover, complex 1 was stable during long-term 
photo-catalysis (2 h, Supplementary Fig. 16). Importantly, the reaction rate was not affected 
by NaN3 (1O2 scavenger), and was similar in deionised water (Supplementary Fig. 13). After 
irradiation of 1 and NADH in PBS in air, H2O2 was generated as detected by peroxide 
detection strips (Fig. 3a), and the pH of the reaction solution increased by ca. 2 units 
(Supplementary Fig. 17). 
A Stern−Volmer titration31 was used to study the mechanism of NADH photo-catalysis. 
When the NADH concentration was increased, the phosphorescence intensity of 1 decreased 
gradually with a dynamic quenching rate coefficient of 6.8 ´ 106 (Fig. 3b). The 
phosphorescence lifetime of 1 in air-saturated PBS (330 ns) decreased by ca. 50% after 
addition of NADH (171 ns, Supplementary Fig. 5). 
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Electron paramagnetic resonance (EPR) was used to trap radical intermediates during 
photo-catalytic oxidation of NADH (Fig. 3c) using 5-(2,2-dimethyl-1,3-propoxycyclo-
phosphor-yl)-5-methyl-1-pyrroline-N-oxide (CYPMPO) as the spin trap32. In the presence of 
CYPMPO, a carbon-centred NAD• radical was detected as CYPMPO-NAD together with 
CYPMPO-CH3 after irradiation in PBS/methanol (1:1 v/v, 463 nm, 10 min, 293 K). The •CH3 
radical was generated by a photo-reaction between H2O2 and methanol (Supplementary Fig. 
18). Singlet oxygen production was also detected by EPR, and the quantum yield in 
acetonitrile (0.71) was 7x higher than in PBS (F = 0.11; Supplementary Fig. 19). This is due 
to the longer lifetime of the triplet state in acetonitrile compared to PBS, typical for metal 
complexes having a triplet excited state7,9. 
Molecular adducts of NADH and excited-state *1 were investigated by DFT calculations. 
Stable minima were observed for structures with NADH clamped by p-p interactions over the 
triplet hole orbital localized on the pq ligand (Fig. 3d), and over the triplet particle orbital 
localized on the ttpy p-system (Fig. 3e), structures which would facilitate electron transport 
from NADH to *1. 
 
Photoreduction of cytochrome c under hypoxia 
Under nitrogen, the photo-catalytic activity of 1 decreased significantly (TON = 3.8, 
Supplementary Fig. 20) due to the absence of a terminal electron acceptor. In the 
mitochondrial electron transport chain (ETC), the 12.3 kDa heme protein cyt c transfers 
electrons between Complex III (Coenzyme Q-cyt c reductase) and Complex IV (cyt c 
oxidase)33. Release of cyt c from the mitochondria into the cytoplasm induces cell apoptosis34.  
 The oxidation state of cyt c (Fe2+/Fe3+) can readily be monitored by the b and a bands at 
520 and 550 nm, respectively35. NADH (50 µM) slowly reduced Fe3+-cyt c (11.2 µM; 293 K, 
Supplementary Fig. 20). The reaction was slightly accelerated upon 463 nm light irradiation 
(Supplementary Fig. 21) with low TOF (2.8 h-1, Supplementary Fig. 22). In the absence of 
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NADH, 1 (0.6 µM) did not reduce Fe3+-cyt c, even under light irradiation (Supplementary Fig. 
21). After adding NADH, the rate of photo-reduction of Fe3+-cyt c increased significantly 
(Fig. 3f), with the TOF increasing to 16.7 h-1. When CYPMPO was added to trap NAD•, the 
reduction rate decreased (Supplementary Figs. 21, 22), indicating that NAD•  was involved in 
Fe3+-cyt c photoreduction.   
 
Photo-cytotoxicity and cell death mechanism 
The dark- and photo-cytotoxic activity of 1 was investigated against a range of cancer cell 
lines, and normal cells MRC-5 (human lung fibroblasts) and LO2 (human hepatocyte cell 
line), (Supplementary Figs. 23-26, Supplementary Table 9). Cisplatin and 5-aminolevulinic 
acid (5-ALA) were used as controls (Supplementary Fig. 24). Low dark toxicity was 
observed for both A549 human lung carcinoma (IC50 43.6 µM) and MRC-5 cells (43.2 µM) 
after 2 h drug exposure and 46 h recovery. Complex 1 also showed low dark toxicity towards 
normal LO2 human hepatocyte cells (IC50 = 32 µM). For photo-cytotoxicity screening, A549 
cells were treated with 1 for 2 h, washed, placed in fresh medium, then irradiated with blue 
light for 30 min under normoxia (20% O2, 465 nm, 8.9 J/cm2) or hypoxia (1% O2, 450 nm, 10 
J/cm2), and left for 46 h to recover. Under normoxia, 1 (1.6 µM) exhibited high photo-
cytotoxicity with a photo-cytotoxicity index (PI = dark IC50/light IC50) of 27.2. Interestingly, 
1 exhibited similar photo-cytotoxicity (dark/light 42.5/2.3 µM, PI = 18.5) under hypoxia. In 
addition, we found that complex 1 is active against NCI-H460 (lung), HeLa (cervix), Hep G2 
(liver) and SGC-7901 (gastric) cancer cell lines upon light irradiation under both 20% and 
1% oxygen concentrations with sub-micromolar IC50 values (Supplementary Table 9, 
Supplementary Fig. 23). However, the clinical pro-drug 5-ALA, a precursor of the 
photosensitizer protoporphyrin, was totally inactive under hypoxia after irradiation 
(Supplementary Table 9, Supplementary Fig. 24). The photo-cytotoxicity of complex 1 under 
normoxia was reduced in the presence of NaN3 (1O2 scavenger) and D-mannitol (hydroxyl 
radical scavenger) for A549 cells. However, these ROS inhibitors had no significant 
influence on photo-cytotoxicity under hypoxia (Supplementary Fig. 25, Supplementary Table 
9), suggesting a different cellular response to photo-catalysis. It should be noted that 
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cytotoxicity experiments are very sensitive to experimental conditions, including incubation 
time, irradiation time, light dose, and mode of treatment. Changes in the cytotoxicity of 1, 
cisplatin and 5-ALA were observed with change in the incubation time and mode of 
treatment. As most of complex 1 was taken up by the cells within 2 h of incubation time, in 
all our photocytotoxicity experiments, 2 h of incubation with 1 was used prior to 
photoirradiation. 
To investigate the phototherapeutic efficiency on a solid tumour model, the photo-
cytotoxicity of 1 towards A549 lung cancer multicellular spheroids (MCS)36 of diameter ca. 
800 µm was studied (Supplementary Fig. 27, Supplementary Table 9). Remarkably, using 
two-photon red light irradiation (760 nm, 12 J/cm2), 1 gave a PI of 9.7 (dark/light 12.6/1.3 
µM). Under the same conditions, 5-ALA and cisplatin did not exhibit any significant photo-
cytotoxicity37. 
Inductively coupled plasma-mass spectrometry (ICP-MS) confirmed the high cellular 
uptake of 1 (162 ± 6 ng Ir × 106 cells, 5 µM treatment, 2 h,). Furthermore, co-localization 
imaging and quantification by ICP-MS38 (Fig. 4a and Supplementary Fig. 28) showed that ca. 
90% of Ir from 1 localized in mitochondria. Importantly, pulsed laser phosphorescence 
lifetime imaging39 (Fig. 4b) revealed that 1 has an extremely long phosphorescence lifetime 
in A549 cancer cells (1100 ns, Supplementary Fig. 29). 
Next, we investigated photo-induced intracellular NADH depletion in A549 cells. Under 
normoxia, the intracellular NADH concentration was unaffected after incubation with 
increasing concentrations of 1 in the dark (Fig. 4c). Upon light irradiation, 1 induced a 
dramatic depletion in NADH (ca. 4x at 2 µM) and decreased the concentration of adenosine 
triphosphate (ATP) (Fig. 4d). In addition, the irradiated cells lost their ability to generate 
formazan from 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), a 
reaction which requires NAD(P)H-dependent oxidoreductase enzymes (Supplementary Fig. 
30)40.  
We also explored cellular oxidative stress induced by 1. After light irradiation, a strong 
green fluorescence was observed from the ROS probe DCFH-DA under both normoxia and 
hypoxia (Supplementary Fig. 31). A549 lung cancer multicellular spheroid models (ca. 800 
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µm in diameter) showed that ROS were generated only in the outer regions of the MCS after 
irradiation with 760 nm two-photon light (Supplementary Fig. 32), indicating the formation 
of a hypoxic core in the internal region of the spheroids. These results suggested that 
diffusible ROS species41 such as H2O2 were generated. Indeed, the intracellular H2O2 
concentration increased ca. 2.5x (Fig. 4e) compared to unexposed cells. Moreover, the 
cellular H2O2 concentration was significantly lower in the presence of N-acetyl-L-cysteine 
(Fig. 4f), a known ROS scavenger42.  
 
A decrease in the mitochondrial membrane potential (MMP) was observed in 1-treated 
A549 cells after irradiation under both normoxia and hypoxia (Supplementary Figs. 33, 34), 
indicating disruption of the mitochondrial ETC43. However, 1 did not induce any significant 
change in MMP in MRC-5 normal cells in the dark. Furthermore, staining of cells with the 
green fluorescent FTIC-Annexin V conjugate was observed (Supplementary Fig. 35), 
indicating cell apoptosis. Moreover, these cells also showed red fluorescence on co-staining 
with propidium iodide (PI). Apoptotic cells would not allow PI to enter cells, and hence cell 
death may involve an immunogenic-apoptotic mechanism44. We also performed cell 
membrane calreticulin immunofluorescence and an Enzyme-linked Immunosorbent Assay 
(ELISA) for high mobility group box 1 protein (HMGB1) (Supplementary Fig. 36). 
Calreticulin transfer to the outer cell membrane and release of HMGB1 are well known 
markers of immunogenic cell death44. Calreticulin transfer to the outside of the cell 
membrane, detected by Alexa Fluor 488 linked calreticulin antibody, was observed in the 1-
treated A549 cancer cells upon light irradiation. We also detected release of HMGB1 at the 
same time. Both these findings, along with the Annexin V /PI assay, confirmed that complex 
1 induces immunogenic-apoptotic cell death upon light irradiation. 
 
Discussion 
Catalytic metallodrugs activated at low doses have the potential to increase the efficacy of 
cancer therapy45. However, controlling catalytic activity in complicated tissue and cell 
environments as well as selectivity between normal and cancer cells is extremely challenging. 
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In contrast to chemotherapy, PDT provides light-directed cancer-cell-targeted treatment and 
can avoid drug resistance12. However, cancer cells grow under hypoxia and thus the oxygen-
dependent MOA of PDT remains a problem, as is photo-degradation of photosensitisers46. 
Hence we have now designed a stable photo-redox catalyst with an oxygen-independent 
MOA as a new strategy to overcome these problems. 
Our photo-redox catalytic approach recognises two key vulnerabilities in cancer cells. 
Firstly, the mitochondrial ETC contributes to tumourigenic phenotype amplification, cell 
proliferation, and especially cell survival under hypoxia23. Secondly cancer cells are under 
constant oxidative stress47. Coenzyme NADH not only provides electrons for the ETC, but 
also maintains the cellular redox balance and participates in enzyme reactions24. Photo-
catalytic NADH depletion and ETC disruption can therefore achieve selective attack on 
cancer cells and high anticancer activity under hypoxia. 
The novel octahedral Ir(III) photocatalyst 1 was synthesised as a single isomer driven by 
the tridentate ligand ttpy. The X-ray structure and DFT calculations show formation of the 
trans C-Cl isomer, with the negatively-charged C ligand exerting a strong trans influence on 
the Ir-Cl bond. The special ligand coordination architecture tunes the Ir(III) coordination 
sphere, and ensures well-partitioned HOMO and LUMO within the structure, thus 
significantly enhancing dark- and photo-stability48. In contrast, the Ir(III) photo-catalyst 
[Ir(ppy)2(bpy)]+ (ppy = 2-phenylpyridine, bpy = 2,2'-bipyridine) is not photo-stable and 
undergoes photodecomposition during long-term light irradiation49. Moreover, the presence 
of a single cyclometalated chelated ligand decreases the electron density at Ir(III), thereby 
significantly increasing the excited-state redox potential of 1.   
NADH oxidation is usually associated with one-step hydride transfer to substrates, as 
observed for example in transfer hydrogenation using Cp*-iridium(III) catalysts28. However, 
initial one-electron transfer is also known50, e.g. in thermal reactions of [Ru(bpy)3]3+ with 
NADH analogues BNAH (1-benzyl-1,4-dihydronicotinamide)51, and UVA-induced electron 
transfer from NADH to generate superoxide for DNA cleavage52. Other reports have also 
used NADH as an electron donor in photosensitisation53; however, electron transfer between 
a PS and NADH has been little investigated. Our DFT calculations reveal the formation of 
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“clamped” p-p adducts between excited-state *1 and NADH which can facilitate photo-
induced single electron transfer. As a result, complex 1 achieves high TOF for catalytic 
NADH oxidation (100.4 h-1) on light irradiation.  
The mechanism of the photo-catalytic oxidation of NADH is consistent with the reductive 
quenching cycle shown in Figure 5. Upon light excitation, the highly oxidative excited state 
species *1(IrIII) extracts an electron from 1,4-dihydronicotinamide, forming a highly reductive 
1(IrII) species and NADH+• radicals. NADH+• readily deprotonates to generate the neutral 
carbon-centred NAD• radical. Under normoxia (Figure 5a), oxygen oxidises 1(IrII) to form 
superoxide radicals and regenerates 1(IrIII), completing the photo-catalytic cycle. The 
superoxide radical extracts an electron from NAD•  and consumes two protons from the 
medium as evidenced by the pH increase, forming H2O2 and NAD+. Under hypoxia, Fe3+-cyt 
c is a terminal electron acceptor (Figure 5b). In previous reports, Ru(II)/Ir(III) bis-terpyridyl 
complexes and EDTA radicals exhibited a synergistic effect on Fe3+-cyt c reduction54, 
whereas here, we discovered that NADH can also serve as a biological electron donor in the 
synergistic reduction of Fe3+-cyt c by complex 1 or the related complex [Ir(tpy)2]3+ 
(Supplementary Fig. 22). Thus, we confirmed that photo-reduction of Fe3+-cyt c can arise 
from the synergistic action of NAD• radicals and the highly reducing IrII species in a 
deoxygenated environment. This pathway provides a mechanism for oxygen-independent 
NADH depletion with its downstream effects on a wide variety of cellular redox enzymes and 
pathways, and plays an important role in hypoxic photoredox catalysis in cancer cells. 
 
Although mitochondria are dysfunctional in cancer cells, ROS released from the ETC 
under hypoxia are essential for cancer cell survival and redox regulatory functions55. In our 
system, complex 1 induces significant NADH depletion and ETC disruption only in 
irradiated cancer cells, as indicated by the MMP decrease under both normoxia and hypoxia. 
Moreover, ROS generation in cancer cells indicates oxygen consumption during photo-
catalysis by 1 which can cut off essential mitochondrion-to-cell redox communication for cell 
survival under hypoxia56.  These events lead to the induction of cell apoptosis and necrosis by 
complex 1, features of immunogenic apoptosis57. Calreticulin immunofluorescence and 
12 
 
HMGB1 ELISA assays confirmed this hypothesis44. Immunogenic cell death provides a 
potentially powerful strategy for anticancer therapy58, reinstating the body’s defense against 
cancer.  
In addition, both DFT calculations and experimental data reveal strong near infrared two-
photon absorption of 1, and we have demonstrated promising phototherapeutic effects on 
A549 multicellular lung cancer spheroids. These one-photon and two-photon light activation 
properties of 1 will facilitate a broad application from superficial lesions to solid tumours.  
 
Conclusions 
We report for the first time both aqueous and in-cell photo-catalytic oxidation of coenzyme 
NADH by a metal complex, with a very high TOF. The novel octahedral cyclometalated IrIII 
photoredox catalyst, complex 1, is highly photostable with a long phosphorescence lifetime. 
This catalyst, with its unusually high excited state redox potential, not only generates NAD. 
radicals, but also perturbs electron transfer pathways in mitochondria by reduction of Fe3+-
cytochrome c, inducing redox imbalance in cancer cells. The photoredox catalyst is 
equipotent towards normoxic and hypoxic adherent cancer cells, disrupting the mitochondrial 
membrane potential and inducing immunogenic apoptotic cell death. In contrast, current 
clinical photo-chemotherapeutic agents are less effective in hypoxic environments. Moreover, 
photo-catalyst 1 exhibits low toxicity towards normal cells in the dark, a favorable profile for 
reducing the side-effects of treatment. Complex 1 with its photo-controlled oxygen-
independent immunogenic-apoptotic mechanism of cancer cell death is promising for further 
evaluation as a novel targeted anticancer agent.  
 
Methods 
UV-vis studies of complex 1 and NADH reactions. Reactions between complex 1 and 
NADH in various mol ratios were monitored by UV-vis spectroscopy at 310 K in the dark 
and on irradiation with 463 nm light. Turnover number (TON) is defined as the number of 
moles of NADH that a mole of complex 1 can convert within 30 min. Turnover frequency 
(TOF) was calculated from the difference in NADH concentration after 30 min divided by the 
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concentration of complex 1. The concentration of NADH was obtained using the extinction 
coefficient ε339 = 6220 M-1cm-1. 
 
Electron paramagnetic resonance (EPR). EPR spectra were recorded at ambient 
temperature (ca. 293 K) on a Bruker Model A300 ESR spectrometer equipped with a Bruker 
ER 4122 SHQ resonator using 1.0 mm quartz tubes. Typical instrument settings were: 
modulation amplitude 2.0 G and microwave power 0.63 mW, X-band frequency ca. 9.88 
GHz. Spectra were acquired at 20 dB microwave attenuation (non-saturating 2 mW 
microwave power) with modulation amplitude of 0.2 mT peak-to-peak, time constant of 1.28 
ms, receiver gain, 50–200; sweep time, 30 s and conversion time of 5.12 ms. The spin trap 5-
(2,2-dimethyl-1,3-propoxycyclo-phosphoryl)-5-me-thyl-1-pyrroline N-oxide (CYPMPO 1 
mM) was used for NAD• radicals in PBS/methanol (1:1 v/v) containing complex 1 (500 µM, 
methanol) and NADH (10 mM, PBS) under 463 nm irradiation. 
 
Electrochemistry 
Cyclic voltammograms were recorded using a CH Instrument model 600D Electrochemical 
Analyzer/Workstation (Austin, TX). The electrochemical measurements were performed on 
complex 1 (1.0 mM) in acetonitrile solutions containing tetrabutylammonium 
hexafluorophosphate (0.1 M) as supporting electrolyte. The solutions were degassed under 
nitrogen and cyclic voltammograms were scanned from -2.3 V to +2.3 V (three complete 
scans for each experiment). In a typical electrochemical experimental set up, a three-electrode 
system was used: a glassy carbon electrode as the working electrode, Ag/AgCl in 3.0 M KCl 
as the reference electrode, and platinum wire as the counter electrode. CV was performed at a 
scan rate of 100 mV/s. The excited state redox potentials were calculated from the ground 
state redox potentials and the emission maxima to aid evaluation of the photosensitization 
properties of complex 1. Excited state reductive potentials: E([M*]+ /[M]2+) = Eox − Eλem. 
Excited state oxidative potentials: E([M*]+ /[M]0 ) = Ered + Eλem. Eλem = 1240 eV nm /lem. 
 
Data availability 
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The data that support the findings of this study are available within the paper and its 
Supplementary Information files, or from the corresponding authors on reasonable request. 
Crystallographic data for the complex [1]PF6·(1.5 toluene) reported in this Article have been 
deposited at the Cambridge Crystallographic Data Centre, under deposition numbers CCDC 
1840366). After the Open Access agreement has been established, underpinning datasets will 
be deposited in Warwick's Institutional Repository: Warwick Research Archive Portal 
(WRAP), according to the Open Access Agreement. 
 
15 
 
References 
1. Riddell, I. A. & Lippard, S. J. Cisplatin and oxaliplatin: Our current understanding of 
their actions. Met Ions Life Sci. 18, 1-42 (2018).  
2. Meier-Menches, S. M. Gerner, C. Berger, W. Hartinger, C. G. & Keppler, B. K. Structure–
activity relationships for ruthenium and osmium anticancer agents–towards clinical 
development. Chem. Soc. Rev. 47, 909-928 (2018).  
3. Bergamo, A. Dyson, P. J. & Sava, G. The mechanism of tumour cell death by metal-based 
anticancer drugs is not only a matter of DNA interactions. Coord. Chem. Rev. 360, 17-33 
(2018).  
4. Farrer, N. J. Salassa, L. & Sadler, P. J. Photoactivated chemotherapy (PACT): the 
potential of excited-state d-block metals in medicine. Dalton Trans. 48, 10690-10701 
(2009). 
5. Banerjee, S. & Chakravarty, A. R. Metal complexes of curcumin for cellular imaging, 
targeting, and photoinduced anticancer activity. Acc. Chem. Res.  48, 2075-2083 (2015). 
6. Lo, K. K. W. Luminescent rhenium(I) and iridium(III) polypyridine complexes as 
biological probes, imaging reagents, and photocytotoxic agents. Acc. Chem. Res. 48, 
2985-2995 (2015).  
7. Knoll, J. D. & Turro, C. Control and utilization of ruthenium and rhodium metal complex 
excited states for photoactivated cancer therapy. Coord. Chem. Rev. 282, 110-126 (2015). 
8. Liu, J. et al Harnessing ruthenium(II) as photodynamic agents: Encouraging advances in 
cancer therapy. Coord. Chem. Rev. 363, 17-28 (2018). 
9. Heinemann, F. Karges, J. & Gasser, G. Critical overview of the use of Ru (II) polypyridyl 
complexes as photosensitizers in one-photon and two-photon photodynamic therapy.  Acc. 
Chem. Res. 50, 2727-2736, (2017). 
10. Shi, G. et al. Ru(II) dyads derived from α-oligothiophenes: A new class of potent and 
versatile photosensitizers for PDT. Coord. Chem. Rev. 282, 127-138 (2015). 
11. Meggers, E. Asymmetric catalysis activated by visible light. Chem. Commun. 51, 3290-
3301 (2015). 
12. Spring, B. Q. Rizvi, I. Xu, N. & Hasan, T. The role of photodynamic therapy in  
16 
 
overcoming cancer drug resistance. Photochem. Photobiol. Sci. 14, 1476-1491 (2015). 
13. Teicher, B. A. Hypoxia and drug resistance. Cancer Metast. Rev. 13, 139-168 (1994). 
14. Wang, H. P. et al. Phospholipid hydroperoxide glutathione peroxidase protects against 
singlet oxygen-induced cell damage of photodynamic therapy, Free Radical Biol. Med. 30  
825–835 (2001). 
15. Henderson, B. & Miller, A. Effects of scavengers of reactive oxygen and radical species 
on cell survival following photodynamic treatment in vitro: comparison to ionizing 
radiation. Radiat. Res. 108, 196-205 (1986). 
16. Gomer, C. et al. Photodynamic Therapy-mediated oxidative stress can induce the 
expression of heat shock proteins. Cancer Res. 56, 2355-2360 (1996). 
17. Ruhdorfer, S. Sanovic, R. Sander, V. Krammer, B. & Verwanger, T. Gene expression 
profiling of the human carcinoma cell line A-431 after 5-aminolevulinic acid-based 
photodynamic treatment. Int. J. Oncol. 30, 1253-1262 (2007). 
18. Tong, Z. Singh, G. & Rainbow, A. J. Sustained activation of the extracellular signal 
regulated kinase pathway protects cells from photofrin-mediated photodynamic therapy. 
Cancer Res. 62, 5528-5535  (2002). 
19. Edmonds, C. Hagan, S. Gallagher-Colombo, S. M. Busch, T. M. & Cengel, K. A. 
Photodynamic therapy activated signaling from epidermal growth factor receptor and 
STAT3: Targeting survival pathways to increase PDT efficacy in ovarian and lung cancer, 
Cancer Biol. Ther. 13, 1463-1470 (2012). 
20. Assefa, Z. et al. The activation of the c-Jun N-terminal kinase and p38 mitogen-activated 
protein kinase signaling pathways protects HeLa cells from apoptosis following 
photodynamic therapy with hypericin, J. Biol. Chem. 274, 8788–8796 (1999). 
21. Kessel, D. & Erickson, C. Porphyrin photosensitization of multi-drug resistant cell types. 
Photochem. Photobiol. 55, 397-399 (1992).  
22. Hockel, M. & Vaupel, P. Tumor hypoxia: definitions and current clinical, biologic, and 
molecular aspects. J. Natl. Cancer Inst. 93, 266-276 (2001). 
23. Klimova, T. & Chandel, N. S. Mitochondrial complex III regulates hypoxic activation of 
HIF. Cell Death Differ. 15, 660-666 (2008). 
17 
 
24. Chiarugi, A. Dölle, C. Felici, R. & Ziegler, M. The NAD metabolome-a key determinant 
of cancer cell biology. Nat. Rev. Cancer 12, 741-752 (2012). 
25. Prier, C. K. et al. Visible light photoredox catalysis with transition metal complexes: 
applications in organic synthesis. Chem. Rev. 113, 5322-5363 (2013). 
26. Huo, H. et al. Asymmetric photoredox transition-metal catalysis activated by visible light. 
Nature 515, 100-103 (2014). 
27. Demas, J. N. et al. Peer Reviewed: Oxygen Sensors Based on Luminescence Quenching. 
Anal. Chem. 71, 793A-800A (1999). 
28. Liu, Z. et al. The potent oxidant anticancer activity of organoiridium catalysts. Angew. 
Chem. Int. Ed. 53, 3941-3946 (2014). 
29. Ma, J. et al Preparation of chiral-at-metal catalysts and their use in asymmetric 
photoredox chemistry. Nat. Protoc. 13, 605-632 (2018). 
30. Peterson, J. R. Smith, T. A. & Thordarson, P. Synthesis and room temperature photo-
induced electron transfer in biologically active bis (terpyridine) ruthenium(II)–
cytochrome c bioconjugates and the effect of solvents on the bioconjugation of 
cytochrome c. Org. Biomol. Chem. 8, 151-162 (2010). 
31. Boaz, H. & Rollefson, G. K. The quenching of fluorescence. Deviations from the Stern-
Volmer law. J. Am. Chem. Soc. 72, 3435-3443 (1950). 
32. Matsuzaki, S. Kotake, Y. & Humphries, K. M. Identification of mitochondrial electron 
transport chain-mediated NADH radical formation by EPR spin-trapping techniques. 
Biochemistry 50, 10792-10803 (2011). 
33. Lapuente-Brun, E. et al. Supercomplex assembly determines electron flux in the 
mitochondrial electron transport chain. Science 340, 1567-1570  (2013). 
34. Li, H. et al. Cytochrome c release and apoptosis induced by mitochondrial targeting of 
nuclear orphan receptor TR3. Science, 289, 1159-1164  (2000). 
35. Margoliash, E. & Frohwirt, N. Spectrum of horse-heart cytochrome c. Biochem. J. 71, 
570-572 (1959). 
36. Huang, H. et al. Highly charged ruthenium(ii) polypyridyl complexes as lysosome-
localized photosensitizers for two-photon photodynamic therapy. Angew. Chem. Int. Ed. 
18 
 
54, 14049-14052 (2015). 
37. Peng, Q. et al. 5-Aminolevulinic acid-based photodynamic therapy. Cancer 79, 2282-
2308 (1997). 
38. Huang, H. et al. Real-time tracking mitochondrial dynamic remodeling with two-photon 
phosphorescent iridium(III) complexes. Biomaterials 83, 321-331 (2016). 
39. Berezin, M. Y. & Achilefu, S. Fluorescence lifetime measurements and biological 
imaging. Chem. Rev. 110, 2641-2684 (2010). 
40. Berridge, M. V. Herst, P. M. & Tan, A. S. Tetrazolium dyes as tools in cell biology: new 
insights into their cellular reduction. Biotechnol. Annu. Rev. 11, 127-152  (2005). 
41. Waghray, M. et al. Hydrogen peroxide is a diffusible paracrine signal for the induction of 
epithelial cell death by activated myofibroblasts. FASEB J. 19, 854-856 (2005). 
42. He, Y. Y. & Häder, D. P. UV-B-induced formation of reactive oxygen species and 
oxidative damage of the cyanobacterium Anabaena sp.: protective effects of ascorbic acid 
and N-acetyl-L-cysteine. J. Photochem. Photobiol. B 66, 115-124 (2002). 
43. Ricci, J. E. et al. Disruption of mitochondrial function during apoptosis is mediated by 
caspase cleavage of the p75 subunit of complex I of the electron transport chain. Cell, 117, 
773-786 (2004). 
44. Tesniere, A. et al. Immunogenic death of colon cancer cells treated with 
oxaliplatin. Oncogene 29, 482-491 (2010). 
45. Coverdale, J. P. et al. Asymmetric transfer hydrogenation by synthetic catalysts in cancer 
cells. Nat. Chem. 10, 347-354 (2018). 
46. Moan, J. Effect of bleaching of porphyrin sensitizers during photodynamic 
therapy. Cancer lett. 33, 45-53 (1986). 
47. Gorrini, C. Harris, I. S. & Mak, T. W. Modulation of oxidative stress as an anticancer 
strategy. Nat. Rev. Drug Discov. 12, 931-947 (2013).  
48. Porras, J. A. Mills, I. N. Transue, W. J. & Bernhard, S. Highly Fluorinated Ir(III)-
2,2′:6′,2″-Terpyridine–Phenylpyridine–X Complexes via Selective C–F Activation: 
Robust Photocatalysts for Solar Fuel Generation and Photoredox Catalysis. J. Am. Chem. 
Soc. 138, 9460-9472 (2016). 
19 
 
49. Tinker, L. L. et al. Visible light induced catalytic water reduction without an electron 
relay. Chem. Eur. J. 13, 8726-8732 (2007). 
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Figure Captions 
 
Figure 1. Structures and stability of compounds. a) NADH. b) Complex 1, line structure, 
and c) X-ray crystal structure; the counter ion PF6- has been omitted for clarity. 
 
Figure 2. DFT calculations and stability of complex 1. a) Dominant canonical particle-hole 
orbitals with overall contribution to the lowest first triplet state of 1. b) Dominant canonical 
particle-hole orbital representation of the strong TPA intermediate state by non-resonant 3-
state model. c) UV-vis spectra showing the dark stability of 1 in RPMI-1640 cell culture 
medium at 293 K for 24 h. The experiment was repeated three times independently with 
similar results. d) Photostability of the emission of 1 in PBS under continuous 463 nm light 
irradiation for 30 min at 293 K. The experiment was repeated three times independently with 
similar results. 
 
Figure 3 Photoredox reaction between NADH and complex 1 under 463 nm blue-light 
irradiation. a) Photo-catalytic oxidation of NADH (240 µM) by complex 1 (6 µM) in PBS 
monitored by UV-vis spectroscopy; inset: detection of H2O2 after irradiation (D = dark, L = 
light). The experiment was repeated five times independently with similar results. b) 
Stern−Volmer plot showing NADH interacts with the excited state of complex 1. The 
experiment was repeated three times independently with similar results. c) X-band EPR 
spectrum of NAD• radicals trapped by CYPMPO at various times after irradiation with 463 
nm light: CYPMPO-NAD (blue circles, aN = 14.43 G, aH = 20.35 G, aP = 50.72 G), 
CYPMPO-CH3 (red circles, aN = 14.67 G, aH = 20.25 G, aP = 48.92 G). The experiment was 
repeated five times independently with similar results. d) Optimized DFT stable minima for 
NADH-1 (triplet state) structures with NADH clamped around pq or e) ttpy ligands. f) Photo-
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catalytic reduction of oxidised cyt c (11.2 µM) by NADH (50 µM) and complex 1 (0.6 µM), 
inset: dependence of absorbance at 550 nm on irradiation time. The experiment was repeated 
three times independently with similar results. 
 
Figure 4 Cellular localization and cellular response after irradiation. a) One- and two-
photon images of A549 lung cancer cells treated with 1 (5 µM) for 1 h and co-stained with 
mitochondrial and lysosomal dyes. lex/lem: 1 405/562 nm, lysotracker 488/520 nm, 
mitotracker 633/660 nm. The experiment was repeated three times independently with similar 
results. b) Phosphorescence lifetime images of living A549 living cells treated with 1 (5 µM), 
lex/lem: 760/562 nm. The experiment was repeated twice independently with similar results. c) 
NADH concentration, d) ATP concentration, and e) H2O2 concentration, in A549 cells treated 
with various doses of 1 in the dark or light. f) H2O2 concentration in A549 cells after light 
irradiation in the presence or absence of 5 mM N-acetyl-L-cysteine (NAC; cell exposure to 1 
for 2 h, washed, followed by 465 nm light irradiation 8.9 J/cm2). RLU: relative luminescence 
unit. Figure 4c-4f: All the experiments were performed as duplicates of triplicates (n=6 
biologically independent experiments). Error bars show ±1 s.d. from the mean. Statistics were 
calculated using the two-tailed t-test with unequal variances (Welch’s unpaired t-test) by 
comparing sample treated with the same dose in the presence or absence of light irradiation. 
*p < 0.05, **p < 0.01 ***p < 0.001. p values:  
4c: NADH 0.5 µM (p = 0.0029), 1.0 µM (p = 0.0003), 2.0 µM (p = 0.0002) 
4d: ATP light 1.0 µM (p = 0.0132), 2.0 µM (p = 0.0052) 
4e: H2O2 0.5 µM (p = 0.0048), 1.0 µM (p = 0.0025), 2.0 µM (p = 0.0009) 
4f: +NAC 0.0 µM (p = 0.0009), 0.5 µM (p = 0.0003), 1.0 µM (p = 0.0035), 2.0 µM (p = 
0.0003). 
 
Figure 5. Photo-catalytic cycle for oxidation of NADH by complex 1 showing the 
production of NAD. radicals, involvement of oxygen, and reduction of cytochrome c. a) 
The reductive catalytic cycle under normoxia. b) Catalytic cycle under hypoxia in the 
presence of Fe3+-cyt c as electron acceptor. 
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Table of contents graphic 
 
 
 
Current photodynamic therapy photosensitizers require oxygen, while tumours are often 
hypoxic. An organo-iridium complex with an unusually high redox potential is equally 
effective in normoxia and hypoxia, and kills cancer cells by a unique immunogenic-apoptotic 
mechanism involving efficient photocatalytic oxidation of NADH to NAD radicals, and 
reduction of cytochrome c. 
 
 
